Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Shuang XiaHui GongYi-Chang ZhaoLin GuoYikun WangBikui ZhangMayur SarangdharYoshihiro NoguchiMiao YanPublished in: Cancers (2022)
Our study suggested ICIs, especially nivolumab and atezolizumab, tended to increase the risk of pulmonary sepsis more than other anticancer regimens. Clinicians should be vigilant in the prevention and management of pulmonary sepsis during ICIs therapy.